Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Eriksson
Peter
P
D001241:Aspirin / Q000191:economics / Q000627:therapeutic use; D002545:Brain Ischemia; D000077144:Clopidogrel; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000191:economics; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D012307:Risk Factors; D020521:Stroke / Q000191:economics* / Q000517:prevention & control*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin